Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Importance: Papillary renal cell carcinoma (PRCC) is the most common type of non-clear cell RCC. Because some cases of PRCC are MET-driven, MET inhibition could be a targeted treatment approach. In previous studies, savolitinib (AZD6094, HMPL-504, volitinib), a highly selective MET-tyrosine kinase inhibitor, demonstrated antitumor activity in this patient group. Objective: To determine whether savolitinib is a better treatment option for this patient population, vs standard of care, sunitinib. Design, Setting, and Participants: The SAVOIR phase 3, open-label, randomized clinical trial was a multicenter study carried out in 32 centers in 7 countries between July 2017 and the data cutoff in August 2019. Overall, 360 to 450 patients were to be screened to randomize approximately 180 patients. Patients were adults with MET-driven (centrally confirmed), metastatic PRCC, with 1 or more measurable lesions. Exclusion criteria included prior receipt of sunitinib or MET inhibitor treatment. Overall, 254 patients were screened. Interventions: Patients received 600 mg of savolitinib orally once daily (qd), or 50 mg of sunitinib orally qd for 4 weeks, followed by 2 weeks without treatment. Main Outcomes and Measures: The primary end point was progression-free survival (PFS, assessed by investigator and confirmed by blinded independent central review). Secondary end points included overall survival (OS), objective response rate (ORR), duration of response, and safety/tolerability. Results: At data cutoff, 60 patients were randomized (savolitinib n = 33; sunitinib n = 27); most patients had chromosome 7 gain (savolitinib, 30 [91%]; sunitinib, 26 [96%]) and no prior therapy (savolitinib, 28 [85%]; sunitinib, 25 [93%]). For savolitinib and sunitinib, 4 (12%) and 10 (37%) patients were women, and the median (range) age was 60 (23-78) and 65 (31-77) years, respectively. Following availability of external data on PFS with sunitinib in patients with MET-driven disease, study enrollment was closed. Progression-free survival, OS, and ORR were numerically greater with savolitinib vs sunitinib. Median PFS was not statistically different between the 2 groups: 7.0 months (95% CI, 2.8-not calculated) for savolitinib and 5.6 months (95% CI, 4.1-6.9) for sunitinib (hazard ratio [HR], 0.71; 95% CI, 0.37-1.36; P = .31). For savolitinib and sunitinib respectively, grade 3 or higher adverse events (AEs) were reported in 14 (42%) and 22 (81%) of patients and AE-related dose modifications in 10 (30%) and 20 (74%). After discontinuation, 12 (36%) and 5 (19%) of patients on savolitinib and sunitinib respectively, received subsequent anticancer therapy. Conclusions and Relevance: Although patient numbers and follow-up were limited, savolitinib demonstrated encouraging efficacy vs sunitinib, with fewer grade 3 or higher AEs and dose modifications. Further investigation of savolitinib as a treatment option for MET-driven PRCC is warranted. Trial Registration: ClinicalTrials.gov Identifier: NCT03091192.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz056 · Cited by 1,151
The Epidemiology of Renal Cell Carcinoma
Ljungberg, B., Campbell, S. C., Cho, H. Y., Jacqmin, D., Lee, J. E., Weikert, S., & Kiemeney, L. A. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.049 · Cited by 999
Self-citationHellström (2019) · doi:10.21037/atm · Cited by 798
Zhang, Y., Xia, M., Jin, K., Wang, S., Wei, H., Fan, C., Wu, Y., Li, X., Li, X., Li, G., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0796-y · Cited by 572
Drug Design, Development and Therapy
(2020) · Drug Design Development and Therapy · doi:10.2147/dddt · Cited by 558
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202547 · Cited by 497
Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3383 · Cited by 463
Self-citationArmstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00515-x · Cited by 426
Tannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Dubauskas Lim, Z., Tamboli, P., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 364
Self-citationGenetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics
Linehan, W. M. (2012) · Genome Research · doi:10.1101/gr.131110.111 · Cited by 243
Kroeger, N., Xie, W., Lee, J., Bjarnason, G. A., Knox, J. J., MacKenzie, M. J., Wood, L., Srinivas, S., Vaishamayan, U. N., Rha, S., et al. (2013) · Cancer · doi:10.1002/cncr.28151 · Cited by 232
Self-citationSystemic Therapy for Non–clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis
Vera-Badillo, F. E., Templeton, A. J., Duran, I., Ocana, A., de Gouveia, P., Aneja, P., Knox, J. J., Tannock, I. F., Escudier, B., & Amir, E. (2015) · European Urology · doi:10.1016/j.eururo.2014.05.010 · Cited by 215
Hereditary Kidney Cancer Syndromes
Haas, N. B., & Nathanson, K. L. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2013.10.001 · Cited by 208
Eder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H., Cancilla, B., Chu, F., Hitchcock-Bryan, S., Sherman, L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0574 · Cited by 197
Ou, S.-H. I. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s19045 · Cited by 187
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
Choueiri, T. K., Plimack, E., Arkenau, H.-T., Jonasch, E., Heng, D. Y. C., Powles, T., Frigault, M. M., Clark, E. A., Handzel, A. A., Gardner, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2967 · Cited by 177
Self-citationHGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers
Moosavi, F., Giovannetti, E., Saso, L., & Firuzi, O. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1653821 · Cited by 176
Albiges, L., Guegan, J., Le Formal, A., Verkarre, V., Rioux-Leclercq, N., Sibony, M., Bernhard, J.-C., Camparo, P., Merabet, Z., Molinie, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2173 · Cited by 176
Self-citationPapillary Renal Cell Carcinoma (PRCC): An Update
Akhtar, M., Al‐Bozom, I., & Hussain, T. O. A. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000220 · Cited by 172
Schöffski, P., Woźniak, A., Escudier, B. J., Rutkowski, P. L., Anthoney, A., Bauer, S., Šufliarský, J., van Herpen, C., Lindner, L. H., Grünwald, V., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.014 · Cited by 117
Self-citationMET: roles in epithelial-mesenchymal transition and cancer stemness
Jeon, H.-M., & Lee, J. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.67 · Cited by 116
Self-citationPhase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
Molina, A. M., Feldman, D. R., Ginsberg, M. S., Kroog, G. S., Tickoo, S. K., Jia, X., Georges, M., Patil, S., Baum, M. S., Reuter, V. E., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9491-6 · Cited by 91
Schuller, A. G., Barry, E., Jones, R. D. O., Henry, R. E., Frigault, M. M., Beran, G. J., Linsenmayer, D. C., Hattersley, M. M., Smith, A., Wilson, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2685 · Cited by 83
Self-citationSuárez, C., Larkin, J., Patel, P. M., Valderrama, B. P., Rodríguez‐Vida, A., Glen, H., Thistlethwaite, F. C., Ralph, C., Srinivasan, G., Méndez, M. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01414 · Cited by 80
Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
Escudier, B. J. (2019) · New England Journal of Medicine · doi:10.1056/nejme1900887 · Cited by 71
Gan, H. K., Millward, M., Ye, H., Qi, C., Sai, Y., Su, W., Wang, J., Zhang, L., Frigault, M. M., Morgan, S. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1189 · Cited by 66
Self-citationNon–Clear Cell Renal Cell Carcinomas: From Shadow to Light
Albiges, L. K., Flippot, R., Rioux-Leclercq, N. C., & Choueiri, T. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2531 · Cited by 60
Self-citationTargeted therapies and the treatment of non-clear cell renal cell carcinoma
Joaquim Bellmunt, B., & Dutcher, J. P. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt152 · Cited by 54
Graham, J., Wells, J. C., Donskov, F. N., Lee, J., Fraccon, A. P., Pasini, F., Porta, C., Bowman, I. A., Bjarnason, G. A., Ernst, D. S., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.03.007 · Cited by 48
Self-citationJonasch, E. W., Slack, R. S., Geynisman, D. M., Hasanov, E., Milowsky, M. I., Rathmell, W. K., Stovall, S., Juarez, D., Gilchrist, T. R., Pruitt, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.1485 · Cited by 41
Wong, E. C. L., Lena, R. D., Breau, R. H., Pouliot, F., Finelli, A., Lavallée, L. T., So, A., Tanguay, S., Fairey, A., Rendon, R., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.05.009 · Cited by 31
Cited by
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., Kitamura, H., McKay, R., Porta, C., Procopio, G., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.05.537 · Cited by 369
Self-citationPal, S. K., Tangen, C., Thompson, I. M., Balzer-Haas, N., George, D. J., Heng, D. Y. C., Shuch, B., Stein, M., Tretiakova, M., Humphrey, P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00152-5 · Cited by 287
Self-citationKidney cancer models for pre-clinical drug discovery: challenges and opportunities
Pohl, L., Friedhoff, J., Jurcic, C., Teroerde, M., Schindler, I., Strepi, K., Schneider, F., Kaczorowski, A., Hohenfellner, M., Duensing, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889686 · Cited by 5
Metadata
- Authors
- Choueiri, T. K., Heng, D. Y. C., Lee, J. L., Cancel, M., Verheijen, R. B., Mellemgaard, A., Ottesen, L. H., Frigault, M. M., L’Hernault, A., Szijgyarto, Z., Signoretti, S., & Albiges, L.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-08-01
- Volume
- 6
- Issue
- 8
- Pages
- 1247
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3030472743
- Cited by
- 177
- References
- 36
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.